Taspoglutide
Clinical data | |
---|---|
Routes of administration | subcutaneous |
ATC code | none |
Pharmacokinetic data | |
Bioavailability | N/A |
Identifiers | |
CAS Number | 275371-94-3 |
ChemSpider | none |
UNII | 2PHK27IP3B |
Chemical and physical data | |
Formula | C152H232N40O45 |
Molar mass | 3339.75 g/mol |
(what is this?) (verify) |
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.[1] [2]
Two phase II trials reported it was effective and well tolerated.[3]
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.[6])
In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]
As of May 2013 no new trials had been registered.[9]
Chemistry
Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
See also
- exenatide (Byetta)
- liraglutide (Victoza)
- albiglutide
References
- ↑ "Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials". Business Wire. June 2008.
- ↑ "Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials". June 2008.
- ↑ Baggio; et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide".
- ↑ "Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In The First Phase III Clinical Trial". October 2009.
- ↑ "Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy". February 2010.
- ↑ "A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy".
- ↑ "Roche Halts Trials of Taspoglutide".
- ↑ "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended".
- ↑ Clinical studies of taspoglutide